Skip to main content
RAPS Euro Convergence 2026 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Learning Level: Advanced
Learning Level: Advanced
Learning Level: Expert
Learning Level: Expert
Learning Level: Foundational
Learning Level: Foundational
Learning Level: Intermediate
Learning Level: Intermediate
RAPS Focus
RAPS Focus
Networking Opportunity
Networking Opportunity
Ticketed Event
Ticketed Event
Student Focus
Student Focus
ViewAttendees 1

Pharmaceuticals

One year after – Observations, insights, implications on JCA

Friday, May 8, 2026
11:15 - 12:15 WEST
Location: Auditorium 3
• Matteo Scarabelli (EFPIA): Why JCA – And what is the difference to the regulatory procedure?
• Noemi Manent (EMA): What we do as EMA in relation to JCA
• Daria Mari (Regenold): What is known – and what should be known in regulatory departments?
• Anne Willemsen (ZIN): Observations from the JCA subgroup
• Thomas Ecker (Ecker+Ecker): How to meet the requirements in JCA

Learning Objectives:

  • Basics around Joint Clinical Assessment and how it is linked to MAA procedure
  • Close interaction between regulatory and market access functions is mission critical for Joint Clinical Assessment
  • What is the role of Joint Scientific Advice